    |
|
The market data 2007-2009 included in the tables below have been extracted from the AESGP study "Economic and Legal Framework for Non-Prescription Medicines", June 2010 edition. Data are reported at public price level, i.e. including wholesale and retail margins and Value Added Tax. For those countries reporting market data at other than public price level, the data have been adjusted to public price level according to best estimates.
Note: Some unusual fluctuations in non-euro countries may be due to exchange rate effects.
European pharmaceutical market – 2007-2009
(excluding hospital sales)
At consumer price level (euro millions)
|
|
€ millions |
|
2007 |
2008 |
2009 |
Austria |
3995 |
4292 |
4104 |
Belgium |
4261 |
4484 |
4574 |
Bulgaria |
596 |
680 |
789 |
Croatia |
1516 |
1666 |
1625 |
Czech Republic |
1695 |
1968 |
1588 |
Denmark |
1707 |
1762 |
1753 |
Finland |
2509 |
2653 |
2686 |
France |
31000 |
30000 |
30150 |
Germany |
36600 |
37370 |
37840 |
Greece |
7979 |
8709 |
9549 |
Hungary |
1973 |
2095 |
1950 |
Ireland |
2068 |
2248 |
2333 |
Italy |
19056 |
18872 |
19416 |
Netherlands |
5758 |
5737 |
5730 |
Norway |
2108 |
2092 |
2080 |
Poland |
6321 |
7439 |
6964 |
Portugal |
3577 |
3614 |
3583 |
Romania |
1974 |
2135 |
2180 |
Russian Federation |
9190 |
11570 |
10480 |
Slovak Republic |
745 |
922 |
971 |
Slovenia |
630 |
675 |
706 |
Spain |
14032 |
16056 |
16588 |
Sweden |
3968 |
3940 |
3647 |
Switzerland |
3467 |
3727 |
4015 |
United Kingdom |
26617 |
23653 |
20882 |
EU-27 |
179168 |
181396 |
180063 |
Europe |
193340 |
198359 |
196183 |
Source: AESGP and AESGP National Associations 2010©
Total pharmaceutical market: sales of all medicinal products (excluding hospital sales) at public price level, including Value Added Tax (VAT). |
European non-prescription pharmaceutical market 2007-2009 |
At consumer price level (euro millions) |
As a percentage of the total pharmaceutical market
(excluding hospital sales)
|
|
€ millions |
|
2007 |
2008 |
2009 |
Austria |
339 |
348 |
343 |
Belgium |
665 |
676 |
703 |
Bulgaria |
158 |
192 |
203 |
Croatia |
165 |
177 |
171 |
Czech Republic |
437 |
529 |
515 |
Denmark |
223 |
227 |
240 |
Finland |
273 |
296 |
285 |
France |
5921 |
5500 |
5560 |
Germany |
5869 |
5680 |
5300 |
Greece |
297 |
319 |
337 |
Hungary |
273 |
315 |
309 |
Ireland |
330 |
360 |
369 |
Italy |
2145 |
2160 |
2201 |
Netherlands |
696 |
701 |
725 |
Norway |
253 |
261 |
259 |
Poland |
1702 |
1997 |
1798 |
Portugal |
226 |
229 |
233 |
Romania |
458 |
477 |
453 |
Russian Federation |
3130 |
3650 |
3840 |
Slovak Republic |
171 |
231 |
251 |
Slovenia |
50 |
56 |
64 |
Spain |
1145 |
1747 |
1767 |
Sweden |
367 |
371 |
355 |
Switzerland |
827 |
881 |
952 |
United Kingdom |
4608 |
4094 |
3777 |
EU-27 |
26618 |
26767 |
26046 |
Europe |
30740 |
31475 |
31010 |
|
% |
2007 |
2008 |
2009 |
8.5% |
8.1% |
8.4% |
15.6% |
15.1% |
15.4% |
26.5% |
28.2% |
25.7% |
10.9% |
10.6% |
10.5% |
25.8% |
26.9% |
32.4% |
13.1% |
12.9% |
13.7% |
10.9% |
11.2% |
10.6% |
19.1% |
18.3% |
18.4% |
16.0% |
15.2% |
14.0% |
3.7% |
3.7% |
3.5% |
13.9% |
15.0% |
15.8% |
16.0% |
16.0% |
15.8% |
11.3% |
11.4% |
11.3% |
12.1% |
12.1% |
12.6% |
12.0% |
12.5% |
12.4% |
26.9% |
26.8% |
25.8% |
6.7% |
6.3% |
6.5% |
23.2% |
22.4% |
20.8% |
34.1% |
31.5% |
36.6% |
23.0% |
25.1% |
25.8% |
7.9% |
8.3% |
9.1% |
8.2% |
10.9% |
10.7% |
9.2% |
9.4% |
9.7% |
23.9% |
23.6% |
23.7% |
17.3% |
17.3% |
18.1% |
14.9% |
14.8% |
14.5% |
15.9% |
15.9% |
15.8% |
|
Source: AESGP and AESGP National Associations 2010©
Non-prescription pharmaceutical market: sales of all medicinal products legally available without a medical prescription at public price level, including Value Added Tax (VAT). |
European self-medication pharmaceutical market 2007-2009 |
At consumer price level (euro millions) |
As a percentage of the total pharmaceutical market
(excluding hospital sales)
|
|
€ millions |
|
2007 |
2008 |
2009 |
Austria |
300 |
308 |
307 |
Belgium |
665 |
676 |
703 |
Bulgaria |
158 |
192 |
203 |
Croatia |
165 |
177 |
171 |
Czech Republic |
437 |
529 |
515 |
Denmark |
223 |
227 |
240 |
Finland |
273 |
296 |
285 |
France |
1926 |
1978 |
1989 |
Germany |
4497 |
4350 |
4230 |
Greece |
297 |
319 |
337 |
Hungary |
273 |
315 |
309 |
Ireland |
315 |
333 |
339 |
Italy |
1596 |
1597 |
1603 |
Netherlands |
628 |
635 |
652 |
Norway |
253 |
261 |
259 |
Poland |
1702 |
1997 |
1798 |
Portugal |
226 |
229 |
233 |
Romania |
458 |
477 |
453 |
Russian Federation |
3130 |
3650 |
3840 |
Slovak Republic |
171 |
231 |
251 |
Slovenia |
50 |
56 |
64 |
Spain |
618 |
1744 |
1822 |
Sweden |
367 |
371 |
355 |
Switzerland |
566 |
602 |
651 |
United Kingdom |
3334 |
2880 |
2649 |
EU-27 |
19099 |
20171 |
19775 |
Europe |
22959 |
24600 |
24437 |
|
% |
2007 |
2008 |
2009 |
7.5% |
7.2% |
7.5% |
15.6% |
15.1% |
15.4% |
26.5% |
28.2% |
25.7% |
10.9% |
10.6% |
10.5% |
25.8% |
26.9% |
32.4% |
12.7% |
13.0% |
13.7% |
10.9% |
11.2% |
10.6% |
6.2% |
6.6% |
6.6% |
12.3% |
11.6% |
11.2% |
3.7% |
3.7% |
3.5% |
13.9% |
15.0% |
15.8% |
15.2% |
14.8% |
14.5% |
8.4% |
8.5% |
8.3% |
10.9% |
11.0% |
11.4% |
12.0% |
12.5% |
12.4% |
26.9% |
26.8% |
25.8% |
6.7% |
6.3% |
6.5% |
23.2% |
22.4% |
20.8% |
34.1% |
31.5% |
36.6% |
23.0% |
25.1% |
25.8% |
7.9% |
8.3% |
9.1% |
5.6% |
10.9% |
11.0% |
9.2% |
9.4% |
9.7% |
16.3% |
16.2% |
16.2% |
12.5% |
12.2% |
12.7% |
10.7% |
11.1% |
11.0% |
11.9% |
12.4% |
12.5% |
|
Source: AESGP and AESGP National Associations 2010©
Self-medication pharmaceutical market: all medicinal products bought spontaneously by consumers without a medical prescription at public price level, including Value Added Tax (VAT). |
Self-medication product groups – 2007-2009 |
Cough & Cold |
At consumer price level (euro millions) |
|
€ millions |
|
2007 |
2008 |
2009 |
Austria |
103.0 |
110.4 |
117.4 |
Belgium |
147.2 |
151.7 |
157.0 |
Bulgaria |
39.0 |
46.0 |
50.0 |
Croatia |
40.6 |
44.4 |
47.3 |
Czech Republic |
100.4 |
124.7 |
122.7 |
Denmark |
4.5 |
5.0 |
5.9 |
Finland |
25.3 |
19.5 |
22.8 |
France |
513.0 |
501.0 |
498.0 |
Germany |
1083.0 |
1071.0 |
1103.0 |
Greece |
69.7 |
76.3 |
89.5 |
Hungary |
13.8 |
13.9 |
12.8 |
Ireland |
51.2 |
54.7 |
56.2 |
Italy |
644.0 |
650.0 |
687.0 |
Netherlands |
121.5 |
123.5 |
131.4 |
Norway |
30.8 |
30.6 |
29.4 |
Poland |
358.2 |
414.7 |
407.5 |
Portugal |
66.1 |
65.5 |
73.6 |
Romania |
58.7 |
65.3 |
61.6 |
Russian Federation |
782.0 |
956.0 |
996.0 |
Slovak Republic |
40.0 |
56.9 |
66.6 |
Slovenia |
14.4 |
16.5 |
19.0 |
Spain |
342.0 |
387.0 |
391.0 |
Sweden |
22.0 |
21.8 |
19.6 |
Switzerland |
143.9 |
153.1 |
175.6 |
United Kingdom |
638.1 |
568.9 |
490.7 |
EU-27 |
4485.9 |
4574.9 |
4612.7 |
Europe |
5452.3 |
5728.4 |
5831.6 |
|
Source: AESGP and AESGP National Associations 2010© |
Self-medication product groups – 2007-2009 |
Analgesics |
At consumer price level (euro millions) |
|
€ millions |
|
2007 |
2008 |
2009 |
Austria |
54.1 |
56.3 |
56.9 |
Belgium |
125.8 |
129.9 |
140.3 |
Bulgaria |
37.0 |
42.0 |
44.0 |
Croatia |
28.6 |
29.2 |
33.8 |
Czech Republic |
87.5 |
102.7 |
97.7 |
Denmark |
45.0 |
45.2 |
45.6 |
Finland |
80.0 |
75.8 |
114.7 |
France |
351.0 |
356.0 |
366.0 |
Germany |
456.0 |
438.0 |
423.0 |
Greece |
71.4 |
76.4 |
80.9 |
Hungary |
30.8 |
33.4 |
29.5 |
Ireland |
71.3 |
79.5 |
82.4 |
Italy |
409.0 |
426.0 |
451.0 |
Netherlands |
136.6 |
129.4 |
131.0 |
Norway |
38.2 |
41.9 |
47.7 |
Poland |
245.0 |
414.7 |
308.9 |
Portugal |
41.3 |
43.5 |
45.3 |
Romania |
70.0 |
65.8 |
57.1 |
Russian Federation |
348.0 |
428.0 |
407.0 |
Slovak Republic |
27.7 |
39.4 |
40.9 |
Slovenia |
9.4 |
11.0 |
12.5 |
Spain |
246.0 |
264.0 |
243.0 |
Sweden |
56.5 |
57.4 |
56.2 |
Switzerland |
126.5 |
133.3 |
141.8 |
United Kingdom |
770.5 |
676.9 |
608.3 |
EU-27 |
3459.8 |
3605.2 |
3482.9 |
Europe |
3962.9 |
4195.7 |
4065.4 |
|
Source: AESGP and AESGP National Associations 2010© |
Self-medication product groups – 2007-2009 |
Digestives |
At consumer price level (euro millions) |
|
€ millions |
|
2007 |
2008 |
2009 |
Austria |
41.0 |
43.6 |
50.1 |
Belgium |
136.8 |
140.8 |
141.9 |
Bulgaria |
12.0 |
16.0 |
17.0 |
Croatia |
12.3 |
14.2 |
13.7 |
Czech Republic |
44.5 |
56.4 |
57.0 |
Denmark |
9.9 |
10.8 |
10.5 |
Finland |
41.1 |
38.4 |
62.7 |
France |
269.0 |
264.0 |
277.0 |
Germany |
579.0 |
586.0 |
589.0 |
Greece |
32.6 |
34.5 |
35.2 |
Hungary |
33.0 |
36.1 |
35.0 |
Ireland |
31.0 |
28.0 |
34.9 |
Italy |
418.0 |
420.0 |
414.0 |
Netherlands |
46.3 |
49.3 |
55.3 |
Norway |
26.8 |
26.9 |
30.4 |
Poland |
203.0 |
265.7 |
246.5 |
Portugal |
31.5 |
32.9 |
37.7 |
Romania |
8.5 |
8.7 |
8.1 |
Russian Federation |
889.9 |
1049.0 |
1054.0 |
Slovak Republic |
19.4 |
26.5 |
28.7 |
Slovenia |
6.0 |
6.8 |
6.8 |
Spain |
191.0 |
214.0 |
321.0 |
Sweden |
30.3 |
32.7 |
36.0 |
Switzerland |
44.2 |
47.4 |
46.4 |
United Kingdom |
354.2 |
329.0 |
289.7 |
EU-27 |
2564.8 |
2667.0 |
2784.4 |
Europe |
3510.3 |
3777.6 |
3898.5 |
|
Source: AESGP and AESGP National Associations 2010© |
Self-medication product groups – 2007-2009 |
Skin products |
At consumer price level (euro millions) |
|
€ millions |
|
2007 |
2008 |
2009 |
Austria |
41.9 |
45.2 |
45.1 |
Belgium |
55.1 |
55.0 |
57.2 |
Bulgaria |
9.0 |
12.0 |
14.0 |
Croatia |
6.1 |
8.5 |
8.1 |
Czech Republic |
31.6 |
37.1 |
37.8 |
Denmark |
9.9 |
9.9 |
10.6 |
Finland |
32.7 |
30.2 |
44.5 |
France |
187.0 |
184.0 |
186.0 |
Germany |
385.0 |
374.0 |
380.0 |
Greece |
57.9 |
58.8 |
61.3 |
Hungary |
26.7 |
25.8 |
21.6 |
Ireland |
36.6 |
38.3 |
45.7 |
Italy |
182.0 |
193.0 |
202.0 |
Netherlands |
57.4 |
60.3 |
67.8 |
Norway |
16.3 |
17.6 |
17.1 |
Poland |
117.5 |
147.9 |
147.9 |
Portugal |
33.3 |
33.4 |
33.3 |
Romania |
20.2 |
21.2 |
18.8 |
Russian Federation |
305.0 |
375.0 |
353.0 |
Slovak Republic |
12.1 |
17.1 |
19.2 |
Slovenia |
6.0 |
5.5 |
5.6 |
Spain |
116.0 |
129.0 |
133.0 |
Sweden |
23.5 |
24.5 |
23.4 |
Switzerland |
63.7 |
75.1 |
80.0 |
United Kingdom |
618.1 |
527.6 |
466.1 |
EU-25 |
2075.7 |
2047.4 |
2038.1 |
Europe |
2450.5 |
2506.0 |
2479.2 |
|
Source: AESGP and AESGP National Associations 2010© |
Self-medication product groups – 2007-2009 |
Vitamins & Minerals |
At consumer price level (euro millions) |
|
€ millions |
|
2007 |
2008 |
2009 |
Austria |
69.6 |
74.1 |
75.3 |
Belgium |
38.9 |
40.9 |
44.9 |
Bulgaria |
18.0 |
21.0 |
21.0 |
Croatia |
24.8 |
25.0 |
22.1 |
Czech Republic |
74.1 |
80.6 |
71.4 |
Denmark |
11.1 |
11.1 |
10.8 |
Finland |
29.8 |
27.8 |
30.8 |
France |
84.0 |
85.0 |
89.0 |
Germany |
277.0 |
255.0 |
238.0 |
Greece |
119.0 |
122.4 |
116.4 |
Hungary |
52.8 |
54.8 |
53.1 |
Ireland |
32.5 |
34.2 |
35.2 |
Italy |
158.0 |
140.0 |
119.0 |
Netherlands |
135.0 |
134.8 |
132.1 |
Norway |
7.8 |
8.1 |
8.6 |
Poland |
258.1 |
284.2 |
288.6 |
Portugal |
13.6 |
13.6 |
7.3 |
Romania |
37.8 |
59.3 |
50.0 |
Russian Federation |
150.0 |
162.0 |
137.0 |
Slovak Republic |
32.5 |
37.3 |
36.3 |
Slovenia |
4.7 |
5.3 |
5.5 |
Spain |
140.0 |
159.0 |
182.0 |
Sweden |
56.5 |
51.9 |
43.8 |
Switzerland |
50.5 |
57.0 |
59.9 |
United Kingdom |
492.0 |
404.1 |
363.9 |
EU-27 |
2142.8 |
2104.6 |
2022.9 |
Europe |
2368.1 |
2348.6 |
2241.9 |
|
Source: AESGP and AESGP National Associations 2010© |
|
|
